Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity

Expert Opinion on Drug Safety

Volumn 13, Issue 10, 2014, Pages 1397-1406

  Akmal, Anam ^a   Kung, Jacqueline ^a  

^a Tufts Division of Endocrinology Tufts Endocrinology Clinic   (United States)

Author keywords

Carbimazole; Hepatotoxicity; Methimazole; Propylthiouracil

Indexed keywords

CARBIMAZOLE; PROPYLTHIOURACIL; THIAMAZOLE; ANTITHYROID AGENT;

ARTICLE; BREAST FEEDING; CHILDHOOD DISEASE; DRUG MECHANISM; DRUG USE; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TRANSPLANTATION; PATIENT MONITORING; POPULATION; PREGNANCY; THYROID CRISIS; ADULT; CHILD; COMPARATIVE STUDY; DRUG LABELING; DRUG-INDUCED LIVER INJURY; FEMALE; HYPERTHYROIDISM; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTITHYROID AGENTS; CARBIMAZOLE; CHILD; DRUG LABELING; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPERTHYROIDISM; METHIMAZOLE; PREGNANCY; PROPYLTHIOURACIL; SEVERITY OF ILLNESS INDEX;

EID: 84907276066     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.953796     Document Type: Article

References (79)

1. Cooper DS. Treatment of thyrotoxicosis. 7th edition. Lippincott-Raven, Philadelphia; 1996
2. Kim H, Kim BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 2001;96(1):165-9
3. Williams K, Nayak S, Becker D, et al. Fifty years of experience with propylthiouracil-Associated hepatotoxicity: what have we learned?. J Clin Endocrinol Metab 1997;82(6):1727-33
4. Russo M, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10(8):1018-23
5. Carrion A, Czul F, Arosemena LR, et al. Propylthiouracil-Induced Acute Liver Failure: role of Liver Transplantation. Int J Endocrinol 2010;2010:910636
6. Gürlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism: effect of antithyroid therapy. J Clin Gastroenterol 1997;24(3):180-3
7. Benyounes M, Sempoux C, Daumerie C, et al. Propylthiouracyl-induced severe liver toxicity: an indication for alanine aminotransferase monitoring?. World J Gastroenterol 2006;12(38):6232-4
8. Weiss M, Hassin D, Bank H. Propylthiouracil-induced hepatic damage. Arch Intern Med 1980;140(9):1184-5
9. Miyamura T, Kanda T, Minemura S, et al. Acute liver failure associated with propylthiouracil in a pregnant 26 year old woman. Case Rep Gastroenterol 2013;7:240-4
10. Hayashida C, Duarte AJ, Sato AE, et al. Neonatal hepatitis and lymphocyte sensitization by placental transfer of propylthiouracil. J Endocrinol Invest 1990;13(11):937-41
11. Seidman D, Livni E, Ilie B, et al. Propylthiouracil-induced cholestatic jaundice. J toxicol Clin Toxicol 1986;24:353-60
12. Pacini F, Sridama V, Refetoff S. Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction, and hepatitis with lymphocyte sensitization. J endocrinol Invest 1982;5(6):403-7
13. Parker W. Propylthiouracil-induced hepatotoxicity. Clin Pharm 1982;1(5):471-4
14. Liaw Y, Huang MJ, Fan KD, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 1993;118(6):424-8
15. Lee W. Drug induced hepatotoxicity. N Engl J Med 1995;333(17):1118-27
16. de Campos M, de Vasconselos GB, Pereira MA, et al. Clinical spectrum and therapeutic approach to patients with hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol 2013;6:9-17
17. Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2007;92(6):2157-62
18. Westphal S. Hepatotoxicity from propylthiouracil. South Med J 1994;87(9):943-7
19. Cooper D. Antithyroid drugs. N Engl J Med 2005;352(9):905-17
20. Cui B, Abe M, Hidata S, et al. Autoimmune hepatitis associated with Graves's disease. Intern Med 2003;42(4):331-5
21. Primeggia J, Lewis JH. Gone (from the Physicians' desk reference) but not forgotten: propylthiouracil-Associated hepatic failure: a call for liver test monitoring. J Natl Med Assoc 2010;102(6):531-4
22. Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf) 2012;77(2):310-15
23. Shen C, Zhao CY, Liu F, et al. Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidism and trilogy of Fallot: case report. BMC Gastroenterol 2010;10:93
24. Bahn R, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17(3):456-520
25. Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr(Phila) 1993;32(1):25-9
26. Peter S. Propylthiouracil-Associated hepatitis. J Natl Med Assoc 1991;83(1):75-7
27. Kirkland J. Propylthiouracil-induced hepatic failure and encephalopathy in a child. DICP 1990;24(5):470-1
28. Baker B, Shapiro B, Fig LM, et al. Unusual complications of antithyroid drug therapy: four case reports and review of literature. Thyroidology 1989;1(1):17-26
29. Sequeira E, Wanyonyi S, Dodia R. Severe propylthiouracil-induced hepatotoxicity in pregnancy managed successfully by liver transplantation: a case report. J Med Case Rep 2011;5:461
30. Morris C, Goldstein RM, Cofer JB, et al. An unusual presentation of fulminant hepatic failure secondary to propylthiouracil therapy. Clin Transpl 1989;311
31. O'Grady J, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94(5):1186-92
32. Aydemir S, Ustundag Y, Bayraktaroglu T, et al. Fulminant hepatic failure associated with propylthiouracil: a case report with treatment emphasis on the use of plasmapheresis. J Clin Apher 2005;20(4):235-8
33. Vitug A, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985;21(4):229-34
34. Rivkees S, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010;95(7):3260-7
35. Ohye H, Minagawa A, Noh JY, et al. Antithyroid drug treatment for graves' disease in children: a long-Term retrospective study at a single institution. Thyroid 2014;24(2):200-7
36. Rivkees S, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132041
37. Rivkees S, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol 2010;2010:176970
38. Majeed M, Babu A. Cholestasis secondary to hyperthyroidism made worse by methimazole. Am J Med Sci 2006;332(1):51-3
39. Werner M, Romaldini JH, Bromberg N, et al. Adverse effects related to thionamide drugs and their dose regimen. Am J Med Sci 1989;297(4):216-19
40. Arab D, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995;80(4):1083-5
41. Blom H, Stolk J, Schreuder HB, et al. A case of carbimazole-induced intrahepatic cholestasis. An immunemediated reaction?. Arch Intern Med 1985;145(8):1513-15
42. Gallelli L, Staltari O, Palleria C, et al. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr Drug Saf 2009;4(3):204-6
43. woeber K. Methimazole-induced hepatotoxicity. Endocr Pract 2002;8(3):222-4
44. Hung Y, Yu WK, Chow E. Delayed cholestatic hepatitis due to methimazole. Hong Kong Med J 1999;5(2):200-1
45. Ramos-Bonner L, Goldberg TH, Moyer S, et al. Methimazole-induced cholestatic jaundice in an elderly hyperthyroid patient. Am J Geriatr Pharmacother 2007;5(3):236-40
46. Mikhail N. Methimazole-induced cholestatic jaundice. South Med J 2004;97(2):178-82
47. Martinez-Lopez J, Greenberg SE, Kling RR. Drug-induced hepatic injury during methimazole therapy. Gastroenterology 1962;43:84-7
48. Zhang M, Zhou H, He R, et al. Steroids for the treatment of methimazoleinduced severe cholestatic jaundice in a 74-year-old woman with type 2 diabetes. Endocrine 2010;37(2):241-3
49. Epeirier J, Pageaux GP, Coste V, et al. Fulminant hepatitis after carbimazole and propranolol administration. Eur J Gastroenterol Hepatol 1996;8(3):287-8
50. Sato H, Harada S, Yokoya S, et al. Treatment for childhood-onset Graves' disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid 2007;17(1):67-72
51. Perrild H, Grüters-Kieslich A, Feldt-Rasmussen U, et al. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol 1994;131(5):467-73
52. LaFranchi S. Nelson textbook of pediatrics. 18 edition. Saunders and Elsevier, Philadelphia; 2007
53. Lazar L, Kalter-Leibovici O, Pertzelan A, et al. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85(10):3678-82
54. Jonas M, Eidson MS. Propylthiouracil hepatotoxicity: two pediatric cases and review of the literature. J Pediatr Gastroenterol Nutr 1988;7(5):776-9
55. Sato H, Minagawa M, Sasaki N, et al. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-Term outcome. J Pediatr Endocrinol Metab 2011;24(5-6):257-63
56. Rivkees S, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360(15):1574-5
57. Sipe W, Su M, Posselt A, et al. Propylthiouracil-Associated liver failure presenting as probable autoimmune hepatitis in a child with Graves' disease. Pediatr Transplant 2006;10(4):525-8
58. Garty B, Kauli R, Ben-Ari J, et al. Hepatitis associated with propylthiouracil treatment. Drug Intell Clin Pharm 1985;19(10):740-2
59. Memi E, Karras S, Tzotzas T, et al. Propylthiouracil hepatitis: report of a case and extensive review of the literature. J Pediatr Endocrinol Metab 2012;25(3-4):331-43
60. Bin-Abbas B, Shabib SM, Al-Dekhail WM, et al. Spontaneous recovery of propylthiouracil-induced fulminant hepatic failure in an 8-year old child. Saudi Med J 2007;28(5):804-6
61. Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis: case report and review of the literature. Pediatr Pathol Lab Med 1996;16(5):845-52
62. Chan G, Mandel SJ. Therapy insight: management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab 2007;3(6):470-8
63. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction During pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92(8 Suppl):1-47
64. Alamdari S, Azizi F, Delshad H, et al. Management of hyperthyroidism in pregnancy: comparison of recommendations of american thyroid association and endocrine society. J Thyroid Res 2013;2013:6
65. Andersen S, Olsen J, Wu CS, et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 2013;98(11):4373-81
66. Glinoer D, Cooper DS. The propylthiouracil dilemma. Curr Opin Endocrinol Diabetes Obes 2012;19(5):402-7
67. Taylor P, Bhatt S, Gouni R, et al. A case of propylthiouracil-induced hepatitis during pregnancy. Eur Thyroid J 2012;1(1):41-4
68. Atkins P, Cohen SB, Phillips BJ. Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus. Drug Saf 2000;23(3):229-44
69. Cooper D, Saxe VC, Meskell M, et al. Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J Clin Endocrinol Metab 1982;54(1):101-7
70. Hambleton C BJ, Saggi B, et al. Thyroid storm complicated by fulminant hepatic failure: case report and literature review. Ann Otol Rhinol Laryngol 2013;122(11):679-82
71. Malozowski S, Chiesa A. Propylthiouracil-induced hepatotoxicity and death. Hopefully, never more. J Clin Endocrinol Metab 2010;95(7):3161-3
72. Rivkees S. Pediatric Graves' disease: controversies in management. Horm Res Paediatr 2010;74(5):305-11
73. Cooper D, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009;94(6):1881-2
74. Development EKSNIoCHaH. Hepatic toxicity following treatment for pediatric graves' disease hepatic toxicity following treatment for pediatric graves' disease meeting. Rockville, MD; 2008
75. FDA. Information for healthcare professionals - propylthiouracil-induced liver failure. 2009. Available from: http:// www.fda.gov/Drugs/DrugSafety/Post marketDrugSafetyInformationfor PatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ ucm162701.htm [Cited 1 April 2014]
76. Agency EM. PhVWP Discussions on safety concerns. 2009. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/ Report/2009/12/WC500016972.pdf [Cited 1 April 2014]
77. Agency MaHPR. Summary of product characteristics. 2011. Available from: http://www.mhra.gov.uk/home/groups/ spcpil/documents/spcpil/ con1392966329334.pdf [Cited 1 April 2014]
78. Burch H, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab 2012;97(12):4549-58
79. Emiliano A, Governale L, Parks M. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 2010;95(5):2227-33